CA2699301A1 - Solid dispersion product of n-aryl urea-based drugs - Google Patents

Solid dispersion product of n-aryl urea-based drugs Download PDF

Info

Publication number
CA2699301A1
CA2699301A1 CA2699301A CA2699301A CA2699301A1 CA 2699301 A1 CA2699301 A1 CA 2699301A1 CA 2699301 A CA2699301 A CA 2699301A CA 2699301 A CA2699301 A CA 2699301A CA 2699301 A1 CA2699301 A1 CA 2699301A1
Authority
CA
Canada
Prior art keywords
group
phenyl
amino
alkyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699301A
Other languages
English (en)
French (fr)
Inventor
Rudolf Schroeder
Tanja Heitermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott Gmbh & Co. Kg
Rudolf Schroeder
Tanja Heitermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg, Rudolf Schroeder, Tanja Heitermann filed Critical Abbott Gmbh & Co. Kg
Publication of CA2699301A1 publication Critical patent/CA2699301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2699301A 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs Abandoned CA2699301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
US60/999,618 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Publications (1)

Publication Number Publication Date
CA2699301A1 true CA2699301A1 (en) 2009-04-23

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699301A Abandoned CA2699301A1 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Country Status (18)

Country Link
EP (1) EP2197425A2 (es)
JP (1) JP2011500649A (es)
KR (1) KR20100087170A (es)
CN (1) CN101827584A (es)
AU (1) AU2008313622A1 (es)
BR (1) BRPI0818340A2 (es)
CA (1) CA2699301A1 (es)
CO (1) CO6270206A2 (es)
CR (1) CR11442A (es)
DO (1) DOP2010000117A (es)
EC (1) ECSP10010183A (es)
GT (1) GT201000102A (es)
MX (1) MX2010004291A (es)
PA (1) PA8800101A1 (es)
RU (1) RU2010119929A (es)
UA (1) UA100865C2 (es)
WO (1) WO2009050291A2 (es)
ZA (1) ZA201002095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
US9387208B2 (en) 2011-11-23 2016-07-12 Novartis Ag Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
GT201000102A (es) 2012-03-12
JP2011500649A (ja) 2011-01-06
ECSP10010183A (es) 2010-06-29
DOP2010000117A (es) 2010-05-15
AU2008313622A1 (en) 2009-04-23
CR11442A (es) 2010-09-06
UA100865C2 (ru) 2013-02-11
ZA201002095B (en) 2011-11-30
PA8800101A1 (es) 2009-05-15
BRPI0818340A2 (pt) 2015-04-22
EP2197425A2 (en) 2010-06-23
CO6270206A2 (es) 2011-04-20
WO2009050291A2 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
KR20100087170A (ko) 2010-08-03
RU2010119929A (ru) 2011-11-27
CN101827584A (zh) 2010-09-08
MX2010004291A (es) 2010-08-02

Similar Documents

Publication Publication Date Title
CA2699301A1 (en) Solid dispersion product of n-aryl urea-based drugs
EP1003487B1 (en) Pharmaceutical formulation with controlled release of active substances
US20090143423A1 (en) Solid dispersion product containing n-aryl urea-based compound
KR100672001B1 (ko) 무정형 질산에스테르들 및 그의 약학조성물들
KR100522239B1 (ko) 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
JP2001511796A (ja) 環状四級アンモニウム化合物を経口投与するための乾燥形態の薬学的調合剤
JP2003527424A (ja) オキサゾリジノン錠剤製剤
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
KR20230034207A (ko) 경구용 의약 조성물 및 그 제조 방법
WO2020122244A1 (ja) 錠剤及びその製造方法
WO2021006267A1 (ja) ピラゾール誘導体の塩及びピラゾール誘導体の製剤
WO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
CA3232832A1 (en) Pharmaceutical composition and a process to prepare the same
WO2023195953A1 (en) A film coated tablet comprising selexi̇pag
RU2261095C1 (ru) Лекарственная форма, обладающая нестероидным противовоспалительным действием, и способ ее изготовления
JP2021066715A (ja) イミダフェナシンを含む粒子の製造方法及びその利用
CN116898808A (zh) 一种FXIa的药物组合物及其制备方法与医药用途
TR2021009380A2 (tr) Amorf dapagliflozi̇n ve metformi̇n hi̇droklorür i̇çeren tablet formülasyonlari i̇çi̇n bi̇r proses
TR201605993A1 (tr) Gastroi̇ntesti̇nal hastaliklarin tedavi̇si̇nde kullanilan farmasöti̇k formülasyonlar
FR2913018A1 (fr) Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141017